SOURCE: eLocity Inc.

July 20, 2005 07:10 ET

Wednesday's July 20th Stock Trading Alert

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by eLocity Inc.

SARASOTA, FL -- (MARKET WIRE) -- July 20, 2005 -- eLocity's stocks to watch for Wednesday are -- GeneThera, Inc. (OTC BB: GTHA), Xpention Genetics, Inc. (OTC BB: XPNG), Teva Pharmaceuticals (NASDAQ: TEVA), View Systems, Inc. (OTC BB: VYST).

Investors may want to watch GeneThera, Inc. (OTC BB: GTHA), a molecular biotechnology company that currently provides genetic diagnostic solutions for the veterinary and agricultural industries, with future plans to include the health-care industry. On Tuesday the company announced that with the signing of its first two contracts with Xpention Genetics, Inc. (OTC BB: XPNG), GeneThera has started their transition from a development company to that of a revenue generating commercial enterprise. The company said that it has executed two contracts on May 28, 2005 with Xpention Genetics that calls for GeneThera to provide research services to Xpention for development of a commercial cancer detection test in animals and humans.

The first contract, GeneThera said, runs for one year at $20,000 per month and calls for the company to develop a cancer detection test for animals. The second contract, beginning in August and also running for one year at $10,000 per month, is for GeneThera to extend the test into human testing. GeneThera said a third contract with another company is slated to begin in September at comparable monthly revenues.

Chief Executive Officer Dr. Tony Milici commented on the transition from a research company to a commercial company, saying that GeneThera expects "many more of these type and scope of contracts that should provide the Company with sustainable revenues and the organic growth our business plan outlines."

Shares of GeneThera, Inc. (OTC BB: GTHA) are currently trading at around 71 cents.

Other stocks in the news:

Teva Pharmaceuticals (NASDAQ: TEVA)

Teva Pharmaceuticals announced Tuesday that the FDA has granted tentative approval for the Company's ANDA for Tramadol and Acetaminophen Tablets, 37.5 mg/325 mg, adding that approval is expected upon resolution of patent litigation. Teva Pharmaceuticals also said on Tuesday that global sales of its Copaxone multiple sclerosis drug reached a record $291 million in the second quarter, a 29 percent increase over last year.

Shares of TEVA closed Tuesday's regular trading session at $30.33.

View Systems, Inc. (OTC BB: VYST)

Homeland defense solutions provider, View Systems, Inc., announced Tuesday that the U.S. Department of Energy's Idaho National Laboratory has received a prestigious R&D 100 award for its Hazmat Camera System, marketed by View Systems as the Visual First Responder, a lightweight wireless video camera system that is taken to incident scenes by emergency first responders.

Shares of VYST closed Tuesday's trading session at $0.145.

About eLocity Inc: eLocity owns and operates three financial websites for investors., Featuring active message boards for the penny stock trader, rumors and more., Visit this site for our daily top stock "GRID Makers." We rank stocks on volume, message board activity, sentiment and trend forecast., Bell2Bell features news stories, rumors, the InvestBoard and more.

Sign up for FREE at any of the sites above.

The newsletter is provided by eLocity Inc., an electronic broadcaster and publisher of this newsletter, is here after referred to as "the company." The company received compensation for newsletter and ad services for GTHA (Public Company). The compensation is one thousand dollars from a non-affiliated third party. Because the company received compensation for its services, there is an inherent conflict of interest in the company statements and opinions and such statements and opinions cannot be considered independent.

The company reserves the right to trade in securities mentioned herein, and may make purchases or sales in such securities featured within our newsletter reports. The information contained in this publication is for informational purposes only, and not to be construed as an offer to sell or solicitation of an offer to buy any security. The company makes no representation or warranty relating to the validity of the facts presented nor does the company represent or warrant that all material facts necessary to make an investment decision are presented above. All statements of opinions, if any, (Our Summary) are those of the company.

The company relies exclusively on information gathered on the Public Company, such as public filings, press releases and its web sites. Investors should use the information contained in this publication as a starting point for conducting additional research on the Public Company in order to allow the investor to form his or her own opinion regarding the Public Company. Factual statements contained in this publication are made as of the date stated and they are subject to change without notice. The company is not a registered investment adviser, broker or a dealer.

Investing in the Public Company that this newsletter is providing service for should be reviewed is speculative and a high-risk and may result in the loss of some or all of any investment made in the client. This release may contain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended.

The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements.

Contact Information

  • Contact:
    eLocity Inc.
    Thomas Clay